8月20日，康方生物盘中上涨6.49%，报95.75港元，成交额1.74亿港元。
消息面上，公司将于8月27日发布中期业绩，市场关注依沃西第三适应症（一线鳞状非小细胞肺癌）获批后的放量节奏与利润弹性。机构普遍维持买入评级，野村目标价138.29港元，覆盖机构平均目标价170.79港元，较当前股价存在较大上行空间。此前依沃西第三适应症获批利好于8月12日落地后，股价连续多日遭遇获利回吐，累计从高位回落超10%，短期超卖后叠加业绩预期催化，资金出现回补迹象。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.